3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
5
Withdrawn
2
Unknown
2
Active not recruiting
2
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
513
Leukemia
339
Leukemia, Lymphocytic, Chronic, B-Cell
321
Precursor Cell Lymphoblastic Leukemia-Lymphoma
291
Myelodysplastic Syndromes
233
Lymphoma, Non-Hodgkin
172
Lymphoma
161
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
138
Hematologic Neoplasms
132
Multiple Myeloma
121
Lymphoma, Follicular
120
Lymphoma, Large B-Cell, Diffuse
119
Lymphoma, Mantle-Cell
118
Recurrence
115
Hodgkin Disease
99
Burkitt Lymphoma
99
Lymphoma, B-Cell, Marginal Zone
98
Congenital Abnormalities
78
Leukemia, Myelomonocytic, Chronic
77
Leukemia, Myeloid, Chronic-Phase
68
Neoplasms
67
Myeloproliferative Disorders
65
Lymphoma, Large-Cell, Immunoblastic
64
Blast Crisis
59
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
57
Waldenstrom Macroglobulinemia
53
Primary Myelofibrosis
53
Lymphoma, T-Cell, Cutaneous
52
Leukemia, Myeloid, Accelerated Phase
50
Neoplasms, Plasma Cell
48
Interventions
eltrombopag
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Pathologic Complete Response
×
Other hematologic neoplasm
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts